                                                                                                      TIENTS
                                                                                             A HED 
                                          MORE P ITC                                                                                                ®
                                                            VE SW                                                                           T
                                                    A
                                           H                                                     OEIGH
                                                                                       V                                             ARD b
                                                                             O                                    ANDUNCH
                                                                                                Y ST                              A
                                            TO N N                                                                      E L
                                                                                  A                                 C
                                                                           O                       a SIN
                                             THAN T  rFVIII
                                              HALF-LIFE
                                                                                                                                                  aRecombinant factor VIII.
                                                                                                                                                  b 
                                                                                                                                                    Based on data for Q2 2015-Q1 2016; accounts for net 
                                                                                                                                                               1
                                                                                                                                                              .
                                                                                                                                                    gains and losses of patients switching to and from 
                                            c                                               d half-life rFVIII available for at least 1 year                                                                                                                             32
                                             Based on data for Q2 2015-Q1 2016; accounts for net gains and losses of patients 
                                                                           om standar                                                               standard half-life rFVIII available for at least one year.
                                             switching to and fr                                                    o, NJ.
                                                                                             disk Inc; Plainsbor
                                                        e: 1.   Data on ifle. Novo Nor
                                                   enc
                                                 er
                                             Ref
                          For today’s generation of people  
                          living with hemophilia
                          Novoeight® is designed  
                          to ift into their lives 
                                                                                                                     ®
                            Learn how Novoeight  provides your patients  
                                 storage flexibility they need in their treatment 
                            Discover Novo Nordisk’s continued commitment  
                                 to helping patients with rare bleeding disorders
                            Find out about the support offered by Novo Nordisk
                          Visit Novoeightpro.com today to learn more.
                          Important Safety Information (cont’d)
                          Anaphylaxis and severe hypersensitivity reactions are possible. 
                          Patients may develop hypersensitivity to hamster proteins,  
                          which are present in trace amounts in the product. Should 
                                                                                                                                                                              ®
                          symptoms occur, discontinue Novoeight  and administer 
                          appropriate treatment. 
                          Please see additional Important Safety Information
                          throughout and on page 22.                                                                                           
                          Please see Prescribing Information.
                                                                                       Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
                                                                                                     ®                               ®                                                                                    ™                                  ™
                                                                                       MixPro  and Novoeight  are registered trademarks and NovoSecure                                                                       and QuickCheck                      
                                                                                       are trademarks of Novo Nordisk Health Care AG.
                                                                                       Novo Nordisk is a registered trademark of Novo Nordisk A/S.                                                        
                                                                                       © 2017 Novo Nordisk      Printed in the U.S.A.      USA16HDM04555      January 201                                                                               7
